Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting

It is unclear how treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC) affects real-world patient outcomes. We assessed treatment sequences, patient characteristics and overall survival (OS) in post-docetaxel mCRPC patients. mCRPC patients receiving second-line cabazitaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, William K., Miao, Raymond, Vekeman, Francis, Sung, Jennifer, Cheng, Wendy Y., Gauthier-Loiselle, Marjolaine, Dhawan, Ravinder, Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550521/
https://www.ncbi.nlm.nih.gov/pubmed/28795333
http://dx.doi.org/10.1007/s12032-017-1014-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550521/
https://www.ncbi.nlm.nih.gov/pubmed/28795333
http://dx.doi.org/10.1007/s12032-017-1014-2

Ejemplares similares